RP-A501 Phase 2 pivotal data in Danon disease will determine whether Rocket can build a second approved gene therapy franchise after KRESLADI

Bull

A positive outcome would show durable improvement in cardiac function (e.g., meaningful gains in left ventricular ejection fraction or stabilization of hypertrophic cardiomyopathy) alongside an acceptable safety profile at the recalibrated 3.8×10^13 GC/kg dose with the modified immunomodulatory regimen. This would allow Rocket to align with FDA on pivotal study completion and support a BLA filing, validating RP-A501 as a second approved gene therapy franchise and substantially de-risking the cardiac pipeline's credibility with investors.

Bear

The most likely failure modes are recurrence of serious adverse events (such as the complement-mediated or inflammatory toxicity that triggered the prior clinical hold) at the recalibrated dose, or insufficient evidence of meaningful cardiac benefit in the small patient cohort. Given the ultra-rare nature of Danon disease and the limited number of patients treated, even a single serious safety signal could prompt another clinical hold or program discontinuation, while modest or heterogeneous efficacy signals could fail to support a clear regulatory path.